Category:

Medications

The addition of Trikafta to the RAMQ in September 2021 marks a major advance for cystic fibrosis in Quebec by making available a treatment that acts on the cause of the disease for eligible people.

This study shows that delayed access to Trikafta would lead to more serious lung diseases, more exacerbations, more deaths, and significantly lower life expectancy in people with cystic fibrosis compared to early access.

Scientific advances in cystic fibrosis are major, but access to treatments remains unequal. A call for equity and mobilization.

A critical look at therapeutic progress and inequalities in access to cystic fibrosis treatments.

An awareness-raising article that explains the effects of alcohol in people living with cystic fibrosis and offers concrete guidelines for responsible consumption.

Ventolin is a bronchodilator used to quickly relieve shortness of breath and improve breathing in people living with lung disease, including cystic fibrosis.